Meeting
2023 ASCO Annual Meeting
Interim analysis of a phase II study of nivolumab/ipilimumab plus cabozantinib in patients with unresectable advanced melanoma.
Authors
Geoffrey Thomas Gibney
Georgetown - Lombardi Comprehensive Cancer Center, Washington, DC
Geoffrey Thomas Gibney , Andrew L Pecora , Suthee Rapisuwon , Kevin Chen , Kellie Gardner , Gayle Cramer , Danielle Blair , Amy Avergas , Nicole Swanson , Jaeil Ahn , Michael B. Atkins
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04091750
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9563)
DOI
10.1200/JCO.2023.41.16_suppl.9563
Abstract #
9563
Poster Bd #
326
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition.
First Author: Ahmad A. Tarhini
Poster
2022 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitor (ICI) rechallenge in advanced melanoma patients responders to a first course of ICI: A multicenter, national, retrospective study of the French group of skin cancers (GCC).
First Author: Charlee Nardin
Poster
2020 ASCO Virtual Scientific Program
A multicenter phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401): Results of expansion cohorts.
First Author: James Lin Chen
Poster
2019 ASCO Annual Meeting
Interim analysis of a phase II study of nivolumab combined with ipilimumab in patients with pediatric solid tumors in adulthood (GETHI021).
First Author: Xabier Mielgo